Floatz logo

Inetetamab

Inetetamab

Fudan UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Inetetamab cohort.

Asset / SponsorPhaseRating
Sacituzumab Tirumotecan
Fudan University
Phase 2CCC

Same molecule, other indications

Inetetamab is also rated in:

breast cancerDormant
BB
Indicative ·
66 / 100
View asset →
HER2 positive breast carcinomaDormant
B
Indicative ·
62 / 100
View asset →
chemotherapy-induced toxicityDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →